Login to Your Account


Two months ahead of its PDUFA date, La Jolla Pharmaceutical Co. has won FDA approval for a new vasopressor capable of increasing blood pressure in adults with septic or other distributive shock.

Tax reform is headed for the Oval Office for a signature, a bill that provides a mixed bag for the life sciences. While the corporate tax rate will fall by double-digit percentage in the years ahead, the orphan drug tax credit is cut in half and the 2.3 percent medical device tax is set to come back into play as of Jan. 1, 2018.

Christmas came early for Aerie Pharmaceuticals Inc. with an FDA approval of Rhopressa (netarsudil) for open-angle glaucoma or ocular hypertension on Monday – or maybe call it an early Valentine's Day gift considering the PDUFA goal date wasn't until Feb. 28, 2018.

More U.S. Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: